Flow cytometric immunophenotyping: Emerging as an important diagnostic tool in the evaluation of cytopenic patients

Leukemia Research

Volumn 33, Issue 8, 2009, Pages 1020-1021

  Stetler Stevenson, Maryalice ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cytopenia; Flow cytometry; Idiopathic cytopenia of uncertain significance; Myelodysplastic syndrome

Indexed keywords

ANTIGEN EXPRESSION; BONE MARROW BIOPSY; CELL DIFFERENTIATION; CELL MATURATION; CYTOPENIA; EDITORIAL; FLOW CYTOMETRY; GRANULOCYTE; HIGH RISK PATIENT; HUMAN; IMMUNOPHENOTYPING; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 67349260185     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.02.029     Document Type: Editorial

References (10)

1. Truong F., Smith B.R., Stachurski D., Cerny J., Medeiros J., Woda B.A., et al. The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow-a prospective study. Leukemia Research 33 (2009) 1039-1046
2. Bowen K.L., and Davis B. Abnormal patterns of expression of CD16(FcR-III) and CD11b (CRIII) antigens by developing neutrophils in the bone marrow of patient's with myelodysplastic syndrome. Laboratory Hematology 3 (1997) 292-298
3. Stetler-Stevenson M., Arthur D., Jabbour N., Xie X.Y., Moldrem J., Barrett A.J., et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 98 (2001) 979-987
4. Maynadie M., Picard F., Husson B., Chatelain B., Cornet Y., Le Roux G., et al. Immunophenotypic clustering of myelodysplastic syndromes. Blood 100 (2002) 2349-2356
5. Wells D.A., Benesch M., Loken M.R., Vallejo C., Myerson D., Leisenring W.M., et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 102 (2003) 394-403
6. Kussick S.J., Fromm J., Rossini A., Li Y., Chang A., Norwood T.H., et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. American Journal of Clinical Pathology 124 2 (2005) 170-181
7. van de Loosdrecht A., Westers T.M., Westra A.H., Dräger A.M., van der Velden V.H., and Ossenkoppele G.J. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 111 (2008) 1067-1077
8. Arroyo J.L., Fernandez M., Hernandez J.M., Orfao A., San Miguel J.F., and del Canizo M.C. Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes: its value in patients without karyotypic abnormalities. Hematology Journal 5 (2004) 227-233
9. Pirruccello S., Young K.H., and Aoun P. Myeloblast phenotypic changes in myelodysplasia. CD34 and CD117 expression abnormalities are common. American Journal of Clinical Pathology 125 (2006) 884-894
10. Valent P.H., Horny P., Bennett J.M., Fonatsch C., Germing U., Greenberg P., et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leukemia Research 31 6 (2007) 727-736